‘Proactive education’ critical to preparing patients for likely biosimilar switch

DENVER — Proactively educating patients on biosimilar efficacy and cost-savings associated with their use can help reduce anxiety and bias if/when their insurance opts to switch, according to a presenter at the Crohn’s and Colitis Congress.“Biosimilars are important because we have seen that health care costs have dramatically increased over the past few years,” Ross M. Maltz, MD, a pediatric gastroenterologist in the Pediatric and Adolescent Inflammatory Bowel Disease Center at Nationwide Children’s Hospital, told attendees. “Based on wholesale acquisitionRead More